Overview

A Study of CNTO 328 in Subjects With Metastatic Renal Cell Carcinoma

Status:
Completed
Trial end date:
2006-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to better understand the safety, tolerability and distribution of CNTO 328 in the bloodstream.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Centocor, Inc.
Treatments:
Antibodies, Monoclonal
Siltuximab